These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 35982806)

  • 1. Comparison of Accuracy in Calculation of Absorbed Dose to the Kidneys Following Radioligand Therapy with
    Mahmoudi E; Pirayesh E; Deevband MR; Amoui M; Rad MG
    Indian J Nucl Med; 2022; 37(2):121-125. PubMed ID: 35982806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-Specific Dosimetry in Radioligand Therapy (RLT) for Metastatic Prostate Cancer Using
    Mahmoudi E; Pirayesh E; Deevband MR; Amoui M; Rad MG; Ghorbani M
    Nucl Med Mol Imaging; 2021 Oct; 55(5):237-244. PubMed ID: 34721716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.
    Delker A; Fendler WP; Kratochwil C; Brunegraf A; Gosewisch A; Gildehaus FJ; Tritschler S; Stief CG; Kopka K; Haberkorn U; Bartenstein P; Böning G
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):42-51. PubMed ID: 26318602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [(177)Lu]DKFZ-PSMA-617.
    Hohberg M; Eschner W; Schmidt M; Dietlein M; Kobe C; Fischer T; Drzezga A; Wild M
    Mol Imaging Biol; 2016 Jun; 18(3):437-45. PubMed ID: 26920354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Accuracy in Calculation of Absorbed Dose to Patients Following Bone Scan with (99m)Tc-Marked Diphosphonates by Two Different Background Correction Methods.
    Shahbazi-Gahrouei D; Damoori M; Tavakoli MB; Moslehi M
    J Med Signals Sens; 2016; 6(1):33-8. PubMed ID: 27014610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.
    Kabasakal L; AbuQbeitah M; Aygün A; Yeyin N; Ocak M; Demirci E; Toklu T
    Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1976-83. PubMed ID: 26227531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of different methods for post-therapeutic dosimetry in [
    Rosar F; Schön N; Bohnenberger H; Bartholomä M; Stemler T; Maus S; Khreish F; Ezziddin S; Schaefer-Schuler A
    EJNMMI Phys; 2021 May; 8(1):40. PubMed ID: 33950333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer.
    Yadav MP; Ballal S; Tripathi M; Damle NA; Sahoo RK; Seth A; Bal C
    Nucl Med Commun; 2017 Jan; 38(1):91-98. PubMed ID: 27782913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Examining Absorbed Doses of Indigenously Developed
    Kamaldeep ; Wanage G; Sahu SK; Maletha P; Adnan A; Suman S; Basu S; Das T; Banerjee S
    Cancer Biother Radiopharm; 2021 Apr; 36(3):292-304. PubMed ID: 32379495
    [No Abstract]   [Full Text] [Related]  

  • 10. Radiation Dosimetry for
    Okamoto S; Thieme A; Allmann J; D'Alessandria C; Maurer T; Retz M; Tauber R; Heck MM; Wester HJ; Tamaki N; Fendler WP; Herrmann K; Pfob CH; Scheidhauer K; Schwaiger M; Ziegler S; Eiber M
    J Nucl Med; 2017 Mar; 58(3):445-450. PubMed ID: 27660138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods.
    Belli ML; Mezzenga E; Di Iorio V; Celli M; Caroli P; Canali E; Matteucci F; Tardelli E; Grassi I; Sansovini M; Nicolini S; Severi S; Cremonesi M; Ferrari M; Paganelli G; Sarnelli A
    J Vis Exp; 2020 Apr; (158):. PubMed ID: 32391816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosimetry and safety of
    Paganelli G; Sarnelli A; Severi S; Sansovini M; Belli ML; Monti M; Foca F; Celli M; Nicolini S; Tardelli E; Marini I; Matteucci F; Giganti M; Di Iorio V; De Giorgi U
    Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3008-3017. PubMed ID: 32430583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resistant Prostate Carcinoma.
    Khawar A; Eppard E; Sinnes JP; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA
    Clin Nucl Med; 2018 Jul; 43(7):486-491. PubMed ID: 29688951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [44Sc]Sc-PSMA-617 Biodistribution and Dosimetry in Patients With Metastatic Castration-Resistant Prostate Carcinoma.
    Khawar A; Eppard E; Sinnes JP; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA
    Clin Nucl Med; 2018 May; 43(5):323-330. PubMed ID: 29485430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical dosimetric studies of
    Meléndez-Alafort L; Ferro-Flores G; Santos-Cuevas C; Ocampo-García B; Turato S; Fracasso G; Bolzati C; Rosato A; De Nardo L
    Med Phys; 2021 Jul; 48(7):4064-4074. PubMed ID: 33966284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosimetry of
    Violet J; Jackson P; Ferdinandus J; Sandhu S; Akhurst T; Iravani A; Kong G; Kumar AR; Thang SP; Eu P; Scalzo M; Murphy D; Williams S; Hicks RJ; Hofman MS
    J Nucl Med; 2019 Apr; 60(4):517-523. PubMed ID: 30291192
    [No Abstract]   [Full Text] [Related]  

  • 17. Dosimetry of
    Sarnelli A; Belli ML; Di Iorio V; Mezzenga E; Celli M; Severi S; Tardelli E; Nicolini S; Oboldi D; Uccelli L; Cittanti C; Monti M; Ferrari M; Paganelli G
    Molecules; 2019 Feb; 24(3):. PubMed ID: 30754620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Translation and First In-Human Use of [
    Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
    Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of absorbed dose for Zr-89, Sm-153 and Lu-177 medical radioisotopes: IDAC-Dose2.1 and OLINDA experience.
    Mostafa MYA; Zakaly HMH; Tekin HO; Issa SAM; Erdemir RU; Zhukovsky M
    Appl Radiat Isot; 2021 Oct; 176():109841. PubMed ID: 34214913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using [
    Santoro L; Mora-Ramirez E; Trauchessec D; Chouaf S; Eustache P; Pouget JP; Kotzki PO; Bardiès M; Deshayes E
    EJNMMI Res; 2018 Nov; 8(1):103. PubMed ID: 30498938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.